MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Total Assets 2011-2026 | PRPH
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.6 M | 89.3 M | 31.4 K | 12.3 M | 20.7 M | 34.2 M | 12.8 M | 14.8 M | 16.1 M | 17.4 M | 16.7 M | 19.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 89.3 M | 31.4 K | 28.4 M |
Quarterly Total Assets ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.7 M | 42 M | 50.1 M | 63.2 M | 91.8 M | 93.7 M | - | 91.9 M | 91.7 M | 91.1 M | 95.4 M | 87.6 M | 97.9 M | 97.9 M | 99.7 M | 89.3 M | 72.6 M | 76.3 M | 85.4 M | 31.4 M | 31.4 M | 31.4 M | 31.4 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 33.7 M | 33.7 M | 33.7 M | 33.7 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 17.4 M | 17.4 M | 17.4 M | 17.4 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 99.7 M | 12.3 M | 39 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.1 | 2.84 % | $ 118 M |  Canada |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
1.93 B | $ 2.64 | 1.35 % | $ 1.38 B | Canada |
 |
Evolus
EOLS
|
226 M | $ 5.68 | 37.53 % | $ 366 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.59 | 6.08 % | $ 10.3 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.81 | -16.81 % | $ 53.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
399 M | $ 40.02 | 3.65 % | $ 1.47 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.65 | 4.89 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.95 | 0.39 % | $ 458 M | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 12.19 | 2.48 % | $ 866 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.67 | -0.87 % | $ 2.07 B | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.87 | 0.01 % | $ 378 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.4 | 2.19 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 0.91 | 1.03 % | $ 21.2 M | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 11.71 | 2.81 % | $ 1.62 B | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.55 | 1.21 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.25 | 1.35 % | $ 23.5 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.53 | 0.4 % | $ 341 M | USA |
 |
Viatris
VTRS
|
50 B | $ 14.74 | -1.04 % | $ 17.7 B | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 22.92 | 3.69 % | $ 1.06 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 4.79 | 2.57 % | $ 144 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.75 | -2.76 % | $ 3.23 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.76 | 1.22 % | $ 36.4 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 6.14 | 3.02 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.74 | -0.36 % | $ 3.4 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 7.33 | -0.48 % | $ 4.53 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |